Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Labianca

Showing results (61-70 of 174) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|May 12, 2012
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II studyAlberto Zaniboni, Enrico Aitini, Sandro Barni, et al.
Journal of Translational Medicine|October 22, 2011
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT studySandro Barni, Roberto Labianca, Giancarlo Agnelli, et al.
Journal of the National Cancer Institute|June 29, 2007
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trialsCornelis J A Punt, Marc Buyse, Claus-Henning Köhne, et al.
Oncology|September 6, 2007
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter studyMarina E Cazzaniga, Luigi Dogliotti, Stefano Cascinu, et al.
Nephron. Clinical Practice|April 22, 2010
Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control studyFlavio Gaspari, Paolo Cravedi, Mario Mandalà, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 31, 2014
Addressing the challenges of pancreatic cancer: future directions for improving outcomesManuel Hidalgo, Stefano Cascinu, Jörg Kleeff, et al.
Journal of Pain and Symptom Management|May 8, 2012
Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic painAugusto Caraceni, Oscar Bertetto, Roberto Labianca, et al.
Journal of Translational Medicine|December 24, 2003
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialMichele Guida, Alessandra Ravaioli, Vanna Chiarion Sileni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trialRuggero Ridolfi, Vanna Chiarion-Sileni, Michele Guida, et al.
Critical Reviews in Oncology/Hematology|December 9, 2008
Rectal cancerMaria Giulia Zampino, Roberto Labianca, Giordano D Beretta, et al.
Pageof 18

Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|May 12, 2012
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II studyAlberto Zaniboni, Enrico Aitini, Sandro Barni, et al.
Journal of Translational Medicine|October 22, 2011
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT studySandro Barni, Roberto Labianca, Giancarlo Agnelli, et al.
Journal of the National Cancer Institute|June 29, 2007
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trialsCornelis J A Punt, Marc Buyse, Claus-Henning Köhne, et al.
Oncology|September 6, 2007
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter studyMarina E Cazzaniga, Luigi Dogliotti, Stefano Cascinu, et al.
Nephron. Clinical Practice|April 22, 2010
Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control studyFlavio Gaspari, Paolo Cravedi, Mario Mandalà, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 31, 2014
Addressing the challenges of pancreatic cancer: future directions for improving outcomesManuel Hidalgo, Stefano Cascinu, Jörg Kleeff, et al.
Journal of Pain and Symptom Management|May 8, 2012
Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic painAugusto Caraceni, Oscar Bertetto, Roberto Labianca, et al.
Journal of Translational Medicine|December 24, 2003
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialMichele Guida, Alessandra Ravaioli, Vanna Chiarion Sileni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trialRuggero Ridolfi, Vanna Chiarion-Sileni, Michele Guida, et al.
Critical Reviews in Oncology/Hematology|December 9, 2008
Rectal cancerMaria Giulia Zampino, Roberto Labianca, Giordano D Beretta, et al.
Pageof 18